• AGC Biologics partnered with Child's Cure Genetic Research on Nov. 10, 2026, to pursue an mRNA treatment for CDKL5 deficiency disorder.
• Early proof-of-concept research will assess a pathway toward clinical development, targeting seizure reduction and improved neurological development.
• Repeatable dosing could provide ongoing protein replacement, potentially complementing gene therapy or offering an alternative for patients unsuitable for that approach.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AGC Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611100900OMX_____CNEWS_EN_GNW9873959_en) on November 10, 2026, and is solely responsible for the information contained therein.